AUPH
- Aurinia Pharmaceuticals Inc.
()
Overview
Company Summary
Aurinia Pharmaceuticals Inc. (AUPH) is a biopharmaceutical company focused on the development and commercialization of therapies for patients with rare autoimmune and inflammatory diseases. The company's primary focus is on advancing treatments for lupus nephritis (LN), a condition characterized by kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease.
AUPH is primarily known for its lead product candidate, voclosporin. Voclosporin is an immunosuppressive drug being developed as a potential treatment for LN. It is designed to target the renin-angiotensin-aldosterone system, which plays a role in immune and inflammatory responses that cause kidney damage in LN patients.
The company is conducting clinical trials to evaluate the safety and efficacy of voclosporin in treating LN. They aim to establish voclosporin as a potential standard of care for patients with this challenging condition. If successful, AUPH's treatment could significantly improve the lives of LN patients and fill a critical unmet medical need.
Apart from LN, Aurinia Pharmaceuticals is also exploring voclosporin's potential for other indications, such as dry eye syndrome and focal segmental glomerulosclerosis (FSGS).
Overall, AUPH is a company dedicated to developing innovative therapies to address unmet medical needs in the field of autoimmune and inflammatory diseases, with a specific focus on lupus nephritis.